“Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%)”, J of Skin, vol. 8, no. 6, p. s421, Nov. 2024, doi: 10.25251/skin.8.supp.421.